2017-03-20,Cerulean And Daré To Host Conference Call On Proposed Transaction On March 23
2017-03-20,Cerulean Pharma And Daré Bioscience Enter Into Stock Purchase Agreement
2017-03-15,Stick to Small, Fast Trades Until the Fed's out of the Way
2017-02-01,Cerulean Announces Review Of Strategic Alternatives
2016-12-04,5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech
2016-11-03,Cerulean Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-27,Cerulean To Host Third Quarter 2016 Conference Call On November 3
2016-10-26,Cerulean Announces Promotion Of Scott Eliasof, PhD To Senior Vice President And Chief Scientific Officer
2016-10-25,First Week of June 2017 Options Trading For Cerulean Pharma (CERU)
2016-10-19,Cerulean Announces Technology Platform Collaboration
2016-10-19,Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement With Aspire Capital Fund, LLC
2016-10-06,Cerulean Announces Data Presentations At The 2016 European Society For Medical Oncology Annual Meeting
2016-08-18,Cerulean Announces Reduction In Force
2016-08-18,Cerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure
2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
2016-08-04,Cerulean Reports Second Quarter 2016 Corporate Highlights And Financial Results
2016-07-28,Cerulean To Host Second Quarter 2016 Conference Call On August 4
2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
2016-06-23,Cerulean Announces First Patient Dosed In Phase 2a Expansion Stage Evaluating CRLX301 In Patients With Advanced Solid Tumors
2016-06-22,Cerulean Announces Publication In Cancer Research
2016-06-14,Cerulean To Present At JMP Securities Life Sciences Conference
2016-06-09,Cerulean Announces Manuscript Published In Annals Of Oncology
2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-05-18,Cerulean To Present At The 2016 ASCO Annual Meeting
2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
2016-05-02,Cerulean Reports First Quarter 2016 Corporate Highlights And Financial Results
2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-04-25,Cerulean To Host First Quarter 2016 Conference Call On May 2
2016-04-19,Cerulean Announces Presentation At 2016 American Association For Cancer Research Annual Meeting Of Stage 1 Data From Phase 2 Trial In Platinum-Resistant Ovarian Cancer
2016-04-05,Cerulean To Present At 15th Annual Needham Healthcare Conference
2016-03-23,Here's Why Cerulean Pharma (CERU) Stock is Spiking Today
2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
2016-03-21,Cerulean Presents CRLX301 Phase 1 Data At The 14th International Congress On Targeted Anticancer Therapies
2016-03-16,Cerulean Announces Data Presentations At The 2016 American Association For Cancer Research Annual Meeting
2016-03-10,Cerulean Reports Fourth Quarter 2015 Corporate Highlights And Financial Results
2016-03-07,Cerulean To Present At Two Upcoming March Conferences
2016-03-03,Cerulean To Host Fourth Quarter 2015 Conference Call On March 10
2016-02-01,Cerulean To Present At Two Upcoming Conferences
2015-12-21,Cerulean Announces Relocation To New Office And Laboratory Space In Waltham, Massachusetts
2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
2015-11-16,Cerulean Reports Third Quarter 2015 Corporate Highlights And Financial Results
2015-11-09,Cerulean Announces Data At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-11-05,Cerulean To Host Third Quarter 2015 Conference Call On November 16
2015-10-27,Cerulean Announces Poster Presentations At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
2015-09-24,Cerulean Appoints David R. Walt, Ph.D. To Board Of Directors
2015-09-08,Cerulean Appoints Adrian Senderowicz, M.D., As Chief Medical Officer
2015-09-03,Cerulean To Present At Two Upcoming Conferences
2015-08-06,Cerulean Reports Second Quarter 2015 Corporate Highlights And Financial Results
2015-08-05,Cerulean To Present At Two Upcoming Conferences
2015-07-30,Cerulean To Host Second Quarter 2015 Conference Call On August 6
2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-06-29,Cerulean Pharma Is Now Oversold (CERU)
2015-06-29,Cerulean Pharma Appoints Stuart A. Arbuckle To Board Of Directors
2015-06-16,Cerulean To Present At The JMP Securities Life Sciences Conference
2015-06-02,Oversold Conditions For Cerulean Pharma (CERU)
2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
2015-05-27,Cerulean Appoints Interim Chief Financial Officer
2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
2015-05-12,Cerulean To Present At The UBS Global Healthcare Conference
2015-05-06,Cerulean Reports First Quarter 2015 Corporate Highlights And Financial Results
2015-04-30,Cerulean To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-29,Cerulean To Host First-Quarter 2015 Conference Call On May 6
2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
2015-04-15,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
2015-04-10,Cerulean Closes Public Offering Of Common Stock
2015-04-08,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-07,Cerulean Announces Pricing Of Public Offering Of Common Stock
2015-03-30,Cerulean Announces Proposed Public Offering Of Common Stock
2015-03-20,Cerulean Appoints Chris Guiffre President & Chief Executive Officer
2015-03-19,Cerulean Reports Fourth Quarter 2014 Corporate Highlights And Financial Results
2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
2015-03-12,Cerulean To Host Fourth-Quarter And Year-End 2014 Conference Call On March 19
2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-03-02,Cerulean To Present At Two Upcoming Conferences
2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
2015-02-03,Cerulean To Present At Two Upcoming Conferences
2015-01-29,Cerulean Appoints Vice President, Clinical Operations
2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
2015-01-08,Cerulean Secures Debt Facility From Hercules Technology Growth Capital Of Up To $26.0 Million
2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
2014-12-17,Cerulean Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors
2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2014-11-13,Cerulean Reports Third-Quarter 2014 Corporate Highlights And Financial Results
2014-10-30,Cerulean To Host Third-Quarter 2014 Conference Call On November 13
2014-10-27,Cerulean Pharma Appoints David Parkinson, M.D., To Board Of Directors
2014-10-27,Cerulean Announces Management Changes
2014-10-08,Cerulean Appoints Susan L. Kelley, M.D., To Its Board Of Directors
2014-10-06,Cerulean Appoints Vice President, Regulatory Affairs
2014-09-29,Cerulean Appoints General Counsel
2014-09-18,Cerulean To Present At BioCentury's Newsmakers In Biotechnology Conference
2014-08-12,Cerulean Reports Second Quarter 2014 Corporate Highlights And Financial Results
2014-08-06,Cerulean To Present At Upcoming Conferences
2014-08-05,Cerulean To Report Second Quarter 2014 Corporate Highlights And Financial Results On August 12, 2014
,
,
2017-03-20,Cerulean And Daré To Host Conference Call On Proposed Transaction On March 23
2017-03-20,Cerulean Pharma And Daré Bioscience Enter Into Stock Purchase Agreement
2017-03-15,Stick to Small, Fast Trades Until the Fed's out of the Way
2017-02-01,Cerulean Announces Review Of Strategic Alternatives
2016-12-04,5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech
2016-11-03,Cerulean Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-27,Cerulean To Host Third Quarter 2016 Conference Call On November 3
2016-10-26,Cerulean Announces Promotion Of Scott Eliasof, PhD To Senior Vice President And Chief Scientific Officer
2016-10-25,First Week of June 2017 Options Trading For Cerulean Pharma (CERU)
2016-10-19,Cerulean Announces Technology Platform Collaboration
2016-10-19,Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement With Aspire Capital Fund, LLC
2016-10-06,Cerulean Announces Data Presentations At The 2016 European Society For Medical Oncology Annual Meeting
2016-08-18,Cerulean Announces Reduction In Force
2016-08-18,Cerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure
2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
2016-08-04,Cerulean Reports Second Quarter 2016 Corporate Highlights And Financial Results
2016-07-28,Cerulean To Host Second Quarter 2016 Conference Call On August 4
2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
2016-06-23,Cerulean Announces First Patient Dosed In Phase 2a Expansion Stage Evaluating CRLX301 In Patients With Advanced Solid Tumors
2016-06-22,Cerulean Announces Publication In Cancer Research
2016-06-14,Cerulean To Present At JMP Securities Life Sciences Conference
2016-06-09,Cerulean Announces Manuscript Published In Annals Of Oncology
2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-05-18,Cerulean To Present At The 2016 ASCO Annual Meeting
2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
2016-05-02,Cerulean Reports First Quarter 2016 Corporate Highlights And Financial Results
2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
2016-04-25,Cerulean To Host First Quarter 2016 Conference Call On May 2
2016-04-19,Cerulean Announces Presentation At 2016 American Association For Cancer Research Annual Meeting Of Stage 1 Data From Phase 2 Trial In Platinum-Resistant Ovarian Cancer
2016-04-05,Cerulean To Present At 15th Annual Needham Healthcare Conference
2016-03-23,Here's Why Cerulean Pharma (CERU) Stock is Spiking Today
2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
2016-03-21,Cerulean Presents CRLX301 Phase 1 Data At The 14th International Congress On Targeted Anticancer Therapies
2016-03-16,Cerulean Announces Data Presentations At The 2016 American Association For Cancer Research Annual Meeting
2016-03-10,Cerulean Reports Fourth Quarter 2015 Corporate Highlights And Financial Results
2016-03-07,Cerulean To Present At Two Upcoming March Conferences
2016-03-03,Cerulean To Host Fourth Quarter 2015 Conference Call On March 10
2016-02-01,Cerulean To Present At Two Upcoming Conferences
2015-12-21,Cerulean Announces Relocation To New Office And Laboratory Space In Waltham, Massachusetts
2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
2015-11-16,Cerulean Reports Third Quarter 2015 Corporate Highlights And Financial Results
2015-11-09,Cerulean Announces Data At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-11-05,Cerulean To Host Third Quarter 2015 Conference Call On November 16
2015-10-27,Cerulean Announces Poster Presentations At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
2015-09-24,Cerulean Appoints David R. Walt, Ph.D. To Board Of Directors
2015-09-08,Cerulean Appoints Adrian Senderowicz, M.D., As Chief Medical Officer
2015-09-03,Cerulean To Present At Two Upcoming Conferences
2015-08-06,Cerulean Reports Second Quarter 2015 Corporate Highlights And Financial Results
2015-08-05,Cerulean To Present At Two Upcoming Conferences
2015-07-30,Cerulean To Host Second Quarter 2015 Conference Call On August 6
2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-06-29,Cerulean Pharma Is Now Oversold (CERU)
2015-06-29,Cerulean Pharma Appoints Stuart A. Arbuckle To Board Of Directors
2015-06-16,Cerulean To Present At The JMP Securities Life Sciences Conference
2015-06-02,Oversold Conditions For Cerulean Pharma (CERU)
2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
2015-05-27,Cerulean Appoints Interim Chief Financial Officer
2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
2015-05-12,Cerulean To Present At The UBS Global Healthcare Conference
2015-05-06,Cerulean Reports First Quarter 2015 Corporate Highlights And Financial Results
2015-04-30,Cerulean To Present At The Deutsche Bank 40th Annual Health Care Conference
2015-04-29,Cerulean To Host First-Quarter 2015 Conference Call On May 6
2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
2015-04-15,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
2015-04-10,Cerulean Closes Public Offering Of Common Stock
2015-04-08,Cerulean To Present At 14th Annual Needham Healthcare Conference
2015-04-07,Cerulean Announces Pricing Of Public Offering Of Common Stock
2015-03-30,Cerulean Announces Proposed Public Offering Of Common Stock
2015-03-20,Cerulean Appoints Chris Guiffre President & Chief Executive Officer
2015-03-19,Cerulean Reports Fourth Quarter 2014 Corporate Highlights And Financial Results
2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
2015-03-12,Cerulean To Host Fourth-Quarter And Year-End 2014 Conference Call On March 19
2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
2015-03-02,Cerulean To Present At Two Upcoming Conferences
2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
2015-02-03,Cerulean To Present At Two Upcoming Conferences
2015-01-29,Cerulean Appoints Vice President, Clinical Operations
2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
2015-01-08,Cerulean Secures Debt Facility From Hercules Technology Growth Capital Of Up To $26.0 Million
2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
2014-12-17,Cerulean Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors
2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
2014-11-13,Cerulean Reports Third-Quarter 2014 Corporate Highlights And Financial Results
2014-10-30,Cerulean To Host Third-Quarter 2014 Conference Call On November 13
2014-10-27,Cerulean Pharma Appoints David Parkinson, M.D., To Board Of Directors
2014-10-27,Cerulean Announces Management Changes
2014-10-08,Cerulean Appoints Susan L. Kelley, M.D., To Its Board Of Directors
2014-10-06,Cerulean Appoints Vice President, Regulatory Affairs
2014-09-29,Cerulean Appoints General Counsel
2014-09-18,Cerulean To Present At BioCentury's Newsmakers In Biotechnology Conference
2014-08-12,Cerulean Reports Second Quarter 2014 Corporate Highlights And Financial Results
2014-08-06,Cerulean To Present At Upcoming Conferences
2014-08-05,Cerulean To Report Second Quarter 2014 Corporate Highlights And Financial Results On August 12, 2014
,
,
